Table 1 from Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical
JCM | Free Full-Text | Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
Apixaban for Extended Treatment of Venous Thromboembolism | NEJM
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation - Chao - 2021 - Journal of Arrhythmia - Wiley Online Library
Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical Considerations - American College of Cardiology
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
Frontiers | Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
Target-Specific Oral Anticoagulants
Lillian Sangha, MD ; Benjamin Ravichander, MD ; Navitha Ramesh, MD FCCP
Target-Specific Oral Anticoagulants
DVT Prophylaxis After Hip/Knee Surgery|ELIQUIS® (apixaban) Safety Info
ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS UK
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
Dosing Regimens of Apixaban, Dabigatran Etexilate, Edoxaban, and... | Download Table
Anticoagulation therapy in Atrial Fibrillation patients at high bleeding risk - It's Over 9000!
Missouri Society of Health-System Pharmacists - Pharmacist Continuing Education: From DOACs to ROACs: Strategies for Reversing Oral Anticoagulants
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach | PLOS ONE
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study - ScienceDirect
Abstract 10877: Impact of Blood Concentration of the Direct Oral Anticoagulant Apixaban on Clinical Care of Nonagenarians and the Very Old | Circulation
Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose? | Liao | Kardiologia Polska (Polish Heart Journal)
JCM | Free Full-Text | Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation
Cureus | Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review | Article
Table 1 from Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. | Semantic Scholar
Abstract 11994: Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial | Circulation
View of Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study | Canadian Journal of Hospital Pharmacy
